Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide) and dual GLP-1/GIP agonists (tirzepatide) produce clinically significant weight loss (10-21%) and reduce obesity-related cardiovascular and metabolic complications.
If you have obesity, newer GLP-1 or GLP-1/GIP medications (like semaglutide or tirzepatide) are highly effective, often producing 15-20% weight loss when combined with lifestyle changes. These drugs also significantly improve cardiovascular risk factors. Discuss these options with your doctor, especially if you have a BMI over 30 (or 27 with health issues).
Recently developed drugs and those currently under development have been shown to reduce body weight by more than 10% and are expected to reduce obesity-related complications.
Why this rating
Supported by multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (STEP, SURMOUNT, SCALE).
Source
An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials
Mi-Kyung Kim et al. · Biomolecules & Therapeutics · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →